Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone.
Open Access
- 1 March 1996
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 183 (3), 927-936
- https://doi.org/10.1084/jem.183.3.927
Abstract
An overproduction of proinflammatory cytokines by activated macrophages/monocytes mediates the injurious sequelae of inflammation, septic shock, tissue injury, and cachexia. We recently synthesized a tetravalent guanylhydrazone compound (CNI-1493) that inhibits cytokine-inducible arginine transport and nitric oxide (NO) production in macrophages, and protects mice against lethal endotoxemia and carrageenan-induced inflammation. During these investigations we noticed that CNI-1493 effectively prevented lipopolysaccharide (LPS)-induced NO production, even when added in concentrations 10-fold less than required to competitively inhibit L-arginine uptake, suggesting that the suppressive effects of this guanylhydrazone compound might extend to other LPS-induced responses. Here, we report that CNI-1493 suppressed the LPS-stimulated production of proinflammatory cytokines (tumor necrosis factor [TNF], interleukins 1beta and 6, macrophage inflammatory proteins 1alpha and 1beta) from human peripheral blood mononuclear cells. Cytokine suppression was specific, in that CNI-1493 did not inhibit either the constitutive synthesis of transforming growth factor beta or the upregulation of major histocompatibility complex class II by interferon gamma (IFN-gamma). In contrast to the macrophage suppressive actions of dexamethasone, which are overridden in the presence of IFN-gamma, CNI-1493 retained its suppressive effects even in the presence of IFN-gamma. The mechanism of cytokine-suppressive action by CNI-1493 was independent of extracellular L-arginine content and NO production and is not restricted to induction by LPS. As a selective inhibitor of macrophage activation that prevents TNF production, this tetravalent guanylhydrazone could be useful in the development of cytokine-suppressive agents for the treatment of diseases mediated by overproduction of cytokines.Keywords
This publication has 23 references indexed in Scilit:
- An Inhibitor of Macrophage Arginine Transport and Nitric Oxide Production (CNI-1493) Prevents Acute Inflammation and Endotoxin LethalityMolecular Medicine, 1995
- Microbial superantigens induce NF-kappa B in the human monocytic cell line THP-1.The Journal of Immunology, 1993
- Nitric oxide as a secretory product of mammalian cellsThe FASEB Journal, 1992
- Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.The Journal of Experimental Medicine, 1991
- Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages.JCI Insight, 1990
- Interleukin 1 receptor blockade attenuates the host inflammatory response.Proceedings of the National Academy of Sciences, 1990
- Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis.The Journal of Experimental Medicine, 1989
- Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell killJournal of Immunological Methods, 1989
- Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemiaNature, 1987
- Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype.The Journal of Experimental Medicine, 1986